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Sex-speciﬁc depressive symptoms as markers of
pre-Alzheimer dementia: ﬁndings from the Three-
City cohort study
Joanna Norton1,2, Isabelle Carrière1,2, Karine Pérès3,4, Audrey Gabelle1,2,5, Claudine Berr 1,2, Karen Ritchie1,2,6 and
Marie-Laure Ancelin 1,2
Abstract
Late-life depression, as a potential marker of pre-dementia, has seldom been explored by symptom dimension and
sex, despite sexual dimorphic differences. This study aimed to examine whether speciﬁc depressive dimensions were
associated with pre-Alzheimer’s disease dementia (pre-AD), separately for women and men. Data were drawn from
5617 (58% women) community-dwellers aged 65+ recruited in 1999–2000 and followed at 2-year intervals for
12 years. We used Cox proportional hazard models to study associations between time-dependent Centre for
Epidemiologic Studies-Depression Scale (CES-D) symptom dimensions (namely somatic, depressed, positive affect, and
interpersonal challenge) and pre-AD, deﬁned retrospectively from validated diagnoses established 3.5 (IQR: 3.2–4.0)
years onwards. Analyses were performed according to overall depressive symptomatology (DS+: CES-D score ≥ 16)
and antidepressant/anxiolytic medication use (AA). Results indicated that in DS+women only, all four dimensions
were signiﬁcantly associated with pre-AD in the AA- group, in particular somatic item ‘Mind’ and depressed affect
items ‘Depressed’ and ‘Blues’. The most depression-speciﬁc dimension, depressed affect, was also signiﬁcantly
associated with pre-AD in the DS– AA- women (HR:1.28, 95%CI: 1.12;1.47). In both sexes, in the DS– groups somatic
affect was the most robust pre-AD marker, irrespective of treatment (women: HR= 1.22, 95%CI: 1.08;1.38; men: HR=
1.30, 95%CI: 1.14;1.48). Our ﬁndings highlight sex-speciﬁc associations between depressive symptom dimensions and
pre-AD, modulated by depressive symptomatology and treatment. Assessment of speciﬁc symptom dimensions
taking into account overall symptomatology and treatment could help identify and target high-risk AD-dementia
proﬁles for interventions.
Introduction
Depressive symptoms are common in elderly people
and depression is known to affect up to 50% of persons
with Alzheimer’s disease (AD) dementia1,2. The temporal
course of depression, cognitive impairment and dementia
are known to be closely related1–4, with an ongoing debate
as to the nature and direction of these associations4.
Evidence points to an association between late-life
rather than early or mid-life depression and dementia5–7,
especially in the case of AD8. Findings suggest that
depression acts as a marker of pre-dementia rather than
as a risk factor per se, potentially sharing common
underlying causes such as vascular disease or inﬂamma-
tory processes5–7,9,10. Several prospective studies suggest
that late-life depressive symptoms assessed mostly using
the Centre for Epidemiologic Studies-Depression Scale
(CES-D) may be associated with an increased dementia
risk within a narrow time-frame (between 5 and 10 years)
preceding dementia onset6,9,11–13.
Because the duration of the prodromal phase is uncer-
tain, the time-window in which to consider persons with
dementia as pre-demented needs to be addressed13. This
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is crucial to distinguish depressive symptoms as markers
of the prodromal phase of disease from those (i) too
distant from early symptom onset or (ii) accompanying
the early clinical phases of disease with the possibility of
reverse causality14. So far, differences in study methods
with variability both within15,16 and between6,9 studies in
the time-span between depression assessment and
dementia onset, have made it difﬁcult to compare ﬁnd-
ings. Furthermore, studies do not always distinguish
between the different sub-types of dementia. One study
suggested differential relationships between late-life ver-
sus late-onset depressive symptoms and dementia sub-
types. Indeed, chronic late-life depression was linked to a
greater risk of vascular dementia and late-onset (with no
past) depression to a greater risk of AD dementia8. Dif-
ferent underlying mechanisms could be involved: late-
onset depression may be more likely to reﬂect a pro-
dromal phase of AD whereas late-life depression would ﬁt
better with both the HPA mechanism and vascular-
depression dementia hypotheses. Another cause of con-
cern is that potential sources of bias such as anti-
depressant treatment are not always considered. Yet
residual depressive symptoms due to poor treatment
response should be distinguished from depressive symp-
toms in untreated patients.
Whereas the link between depression and dementia has
been widely explored, few studies have investigated indi-
vidual depressive symptoms or dimensions16–18. Studies
in older adults suggest differential associations between
speciﬁc depression dimensions and various health out-
comes, such as cardio-vascular disease19,20 and cognitive
functioning21,22. Clinically it has been argued that
depression in dementia may have different features from
that in non-demented persons17,23,24. It would be char-
acterised by diminished motivation rather than affective
symptoms, such as sadness and guilt23. In a 5-year follow-
up study of elderly participants with no past depression,
‘loss of interest’ was found to be the only symptom
associated with AD onset16. In a more recent study, the
cognitive/motivational depression dimension predicted
dementia onset, but in non-depressed participants only.
This suggests a differential symptom effect according to
clinical depression status18. However, neither of these
studies considered depressive symptoms or other covari-
ates as time-dependent variables nor deﬁned a speciﬁc
time-window for pre-dementia.
Longitudinal studies investigating the dynamic link
between depression and dementia separately in men and
women are scarce and have used global measures of
depression only7,10,25. Yet, there is evidence that in non-
demented persons the type of depressive symptoms varies
considerably between the sexes26–31. Women tend to
declare more somatic symptoms, such as loss of appetite
and fatigue28,29, whereas men are more likely to see their
life as a failure31. Thus, the type of symptoms associated
with pre-dementia onset may also vary between the sexes.
The aim of our study was to examine in men and women
separately the associations between depression dimensions
and pre-AD dementia (pre-AD) in a 12-year longitudinal
study of non-institutionalised never-depressed elderly
persons. This was performed according to depression
status, taking into account overall symptomatology and
antidepressant or anxiolytic treatment in an attempt to
distinguish the effect of each depressive dimension from
that of depression itself.
Methods
Study design and participants
Data were drawn from the Three-City Study, a multi-
centric prospective cohort study carried out in the French
cities of Bordeaux, Dijon and Montpellier32. Community-
dwelling persons aged 65 and above were recruited ran-
domly from electoral rolls between 1999 and 2000. Par-
ticipants were followed up at approximately 2, 4, 7, 10 and
12 years. The study protocol was approved by the ethics
committees of the University Hospital of Kremlin-Bicêtre
and Sud Mediterranée III (Nîmes). All participants gave
written informed consent.
At each time-point, participants were administered
standardised questionnaires by trained staff with ques-
tions on sociodemographic, lifestyle and health char-
acteristics. Patients were asked to report any chronic
pathologies from a given list. All drugs used regularly over
the past month were recorded and coded according to the
Anatomical Therapeutic Chemical Classiﬁcation (ATC) of
the World Health Organisation. To reduce under-
reporting, participants were asked to provide both medi-
cal prescriptions and drug packages. Fasting blood sam-
ples were taken at baseline for apolipoprotein E (APOE)
ɛ4 genotyping11.
From the original 9294 participants, 216 cases of all-type
dementia at inclusion and 296 cases of non-AD dementia
at follow-up were excluded. A further 1577 participants
with no follow-up data or missing data for AD status at all
follow-ups were removed. As pre-AD at time ‘t’ was
deﬁned as AD onset between the ‘t+ 1’ and ‘t+ 2’ follow-
ups, 101 participants with AD onset between inclusion and
the ﬁrst follow-up visit were excluded. The analysis was
performed on 5617 participants, 2243 men and 3374
women, with no history of major depression (641 exclu-
ded) and no missing values for baseline depressive symp-
tomatology and the main covariates (846 excluded) (see
Fig. S1, ﬂow chart). Participants excluded from the analysis
were more likely to be male, older, APOE ɛ4 carriers, with
lower income and education level, more chronic pathol-
ogies, visual or hearing impairment, and dependency. They
were more likely to have a CES-D score ≥ 16, and use
anxiolytic or antidepressant (AA) medication.
Norton et al. Translational Psychiatry           (2019) 9:291 Page 2 of 10
Variables
AD and pre-AD dementia
A preliminary diagnosis of dementia and its type was
made at each follow-up by the local clinical Three-City
Study investigators according to DSM-IV criteria33. It was
then validated independently by a national panel of neu-
rologists. Date of AD onset was taken to be the midpoint
between the diagnosis follow-up and the prior follow-up.
In our study, participants were considered pre-demented
at time-point ‘t’, two follow-ups prior to the ‘t+ 2’ follow-
up at which AD diagnosis was established for the ﬁrst
time. This corresponds to a median (IQR) duration of 3.5
(3.2–4.0) years, 3.6 (3.2–4.1) years for women and 3.5
(3.1–4.0) years for men, between pre-AD and diagnosis.
This allowed for an intermediate dementia-free time-
point (‘t+ 1’), in order to ensure a 2-year dementia-free
time-lag between depressive symptom assessment and the
beginning of the dementia onset period.
Depressive symptomatology
Depressive symptoms were assessed at inclusion and
each of the follow-ups using the validated 20-item CES-D
scale34. For each item, participants rated how frequently
they applied to them over the past week. Ratings were
based on a 4-point Likert scale ranging from 0 (rarely,
none of the time) to 3 (frequently, most of the time). High
scores on all negatively-worded items reﬂected more
severe symptomatology. For consistency purposes, the
four positive-worded items were reversed so that high
scores reﬂected more severe symptomatology. The CES-D
is generally considered to have a 4-factor structure con-
sisting of depressed affect, somatic affect, positive affect
and interpersonal challenge26, although the exact items
for each dimension vary somewhat from one study to
another26,34–36. Following Carleton’s review of previous
CES-D validation studies26, we chose to use a modiﬁed
4-factor version of the original solution26,34. Scores on the
somatic (seven items) and depressed affect (ﬁve items)
dimensions were standardised to the 0-to-12 scale of the
positive affect and interpersonal challenge dimensions
(four items each) for comparability purposes. We also
distinguished participants with low and high depressive
symptomatology (DS) using the 16+ cut-off on the global
CES-D score37. The Mini International Neuropsychiatric
Interview was used only to identify participants at baseline
with a history of major depression according to DSM-IV
criteria38.
Covariates
Baseline variables: socio-demographic factors included
age, sex and education (>than 5 years). Health and lifestyle
characteristics recorded at baseline only included smok-
ing (never, past, current) and current alcohol consump-
tion (g/day).
Time-dependent variables: these were measured at
baseline and each follow-up and included: living situation
(alone or not), body mass index (BMI) (calculated from
reported height and weight), visual or hearing impair-
ment39, and the following chronic diseases: hypertension
(≥140/90mm Hg or treated), hypercholesterolemia and
diabetes (self-reported or treated), and any self-reported
ischemic disease (angina, coronary angioplasty, cardiac
bypass, myocardial infarction, stroke, arteritis). The
median score on the Mini Mental State Examination
(MMSE) was used as a global measure of cognitive
function40. A hierarchical 3-level measure of dependency
was constructed41, combining the Rosow-Breslau mobility
scale42, the Lawton-Brody Instrumental Activities of Daily
Living scale43 and Katz Activities of Daily Living scale44.
Antidepressant (N06A) and anxiolytic (N05B) medication
use in the past month were recorded at each time-point.
Statistical analysis
The sample was described separately for men and
women at baseline, using percentages for categorical
variables and means (SD) or medians (IQR) for con-
tinuous variables, after testing for normality using the
Shapiro-Wilk test.
All four depression dimension scores and binary DS
were considered independently at baseline and as time-
dependent variables. Statistical tests were performed
using Cox models with delayed entry, with age as the basic
time-scale and birth as the time origin45. This method
enables a better adjustment for age than the standard
model with time since inclusion as the time-scale. Thus,
time-points should be understood as age-points. The
assumptions of proportional hazards over time for base-
line variables and the log-linearity of CES-D scores and
other continuous covariates were veriﬁed. Results were
expressed as hazard ratios (HR) with 95 % conﬁdence
intervals (CI). HRs represent the increased risk per one-
point increase in score on an ordinal 0–12 scale. For the
positive affect and interpersonal challenge dimensions,
this directly represents one additional point on the
0–12 symptom scale; for the depressed and somatic affect
dimensions, this represents 1.25 and 1.75 additional
points on the ﬁve-items (0–15 score) and seven-items
(0–21 score) scales, respectively. For the total score, this
represents a 5-point increase on the 20-item (0–60 score)
scale. For each individual symptom however, the increase
corresponds to a one-point increase on the 0–3 scale.
Covariates were classiﬁed as either ﬁxed and unchan-
ging across the follow-ups or, when data were available, as
time-dependent. Covariates associated with pre-AD in
either sex with p-values < 0.15 were considered for entry
in the multivariate analysis (see Table S1). We further
examined the relationship between symptom dimensions
and pre-AD stratiﬁed by DS and AA use. Finally, we
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examined individual items categorised as binary variables
(score: 0/1+), using Bonferroni correction for multiple
testing. Statistical analyses were performed using SAS
Enterprise Guide Version 7.15 (SAS Institute, Inc. Cary,
North Carolina).
Results
Sample description
Median (IQR) age at inclusion was 73.2 (69.4–77.2) for
women and 72.5 (69.2–76.8) for men. Of the sample,
24.3% of women and 10.6% of men had high DS (Table 1).
Median (IQR) follow-up duration was 10.1 (IQR=
6.9–11.3) and 9.1 (6.3–11.2) years, for women and men
respectively. There were 294 AD cases at follow-up for the
women and 139 cases for the men.
Association between depressive symptom dimensions and
pre-AD dementia
For women only, all four dimensions were associated
with pre-AD. The strongest association was observed for
the somatic affect dimension (Table 2). The somatic and
depressed affect dimensions were signiﬁcantly associated
with pre-AD irrespective of DS, whereas the remaining
two dimensions were associated in the DS+ group only
(Table 3). More speciﬁcally, in the DS– group, the asso-
ciation for somatic affect was signiﬁcant in the treated
women only. For somatic affect in the AA- women, we
removed covariates one by one from the model and the
association was signiﬁcant when excluding time-
dependent dependency (p= 0.03) (data not shown). In
the DS+ group, the four dimensions were signiﬁcantly
associated with pre-AD in the untreated women only.
Further adjusting for continuous time-dependent MMSE
score did not modify the ﬁndings (data not shown).
For men, the somatic affect and interpersonal challenge
dimensions were both signiﬁcantly associated with pre-
AD in the DS– group, irrespective of treatment for
somatic affect only; this was also the case for positive
affect in the DS+ group. The results were unchanged
when further adjusting for MMSE score (data not shown).
The effect of AA use could not be examined in the DS+
group due to low number of events (21) and AA users (5).
Association between individual depressive symptoms and
pre-AD dementia
Associations for women between individual items and
pre-AD are shown in Fig. 1, with an indication of sig-
niﬁcance after multiple comparison correction. Associa-
tions further differed according to DS and AA use. For
instance, somatic affect item ‘Bothered’ remained highly
signiﬁcantly associated with pre-AD in the DS– group
only, and more speciﬁcally in the AA+women (see Table
S2). Conversely, ‘Mind’, ‘Blues’, ‘Depressed’, ‘Sad’ and
‘Dislike’ were highly signiﬁcantly associated with pre-AD
in the DS+ group, with strongest associations in the
untreated women.
For men, only somatic affect items ‘Mind’ and ‘Fearful’
remained signiﬁcant after multiple comparison correction
(Fig. 2), and they were also highly signiﬁcant in the DS–
group (HR= 2.03 (1.39;2.98), p= 0.0003 and HR= 2.37
(1.0;3.74), p= 0.0002, respectively).
Table 1 Socio-demographic, lifestyle and health
characteristics of the sample at baseline, for women and
men separatelya
Women
(N= 3374)
Men
(N= 2243)
% % pd
Centre
Bordeaux 23.8 23.1
Dijon 57.4 53.7
Montpellier 18.8 23.3 0.0002
Age (years) (median, IQR) 73.2
(69.4–77.2)
72.5
(69.2–76.9)
0.004
Education (>5 years) 75.3 78.6 0.005
Living alone 48.2 13.9 <0.0001
Smoking
Never 81.9 31.3
Former 14.4 60.6
Current 3.7 8.1 <0.0001
Alcohol consumption (g/day)
(median, IQR)
4.5 (0–11.0) 19.2 (2.3–30.5) <0.0001
BMI (kg/m2) (mean, SD) 25.4 (4.3) 26.2 (3.4) <0.0001
Chronic diseases
Hypertension 73.9 64.1 <0.0001
Hypercholesterolemia 39.4 34.2 <0.0001
Diabetes 5.6 9.9 <0.0001
Ischemic disease 11.3 20.7 <0.0001
MMSE score (median, IQR) 28 (27–29) 28 (27–29) 0.29
Visual or hearing impairment 18.8 18.2 0.55
Dependency level
Low (or fully independent) 50.0 69.3
Moderate (mobility
restriction only)
42.3 26.0
High (IADL and/or ADL
limitation)
7.7 4.7 <0.0001
Anxiolytic consumption 17.2 7.6 <0.0001
Antidepressant consumption 7.0 2.4 <0.0001
APOE ɛ4 carrier 19.3 20.2 0.40
CES-D dimensions (median, IQR)
Somatic affectb 1.7 (0.6–2.9) 1.1 (0.6–2.3) <0.0001
Depressed affectb 0.8 (0–3.2) 0 (0–0.8) <0.0001
Positive affectc 3.0 (1–6) 2.0 (0–4) <0.0001
Interpersonal challenge 0 (0–2) 0 (0–1) <0.0001
Total CES-D score 9 (4–15) 6 (2–10) <0.0001
Depressive symptomatology:
high (CES-D≥16)
24.3 10.6 <0.0001
aless than 1% missing values except for alcohol consumption (6.5%)
bstandardised to 0–12 scale
creversed so that a high score reﬂects low positive affect
dχ2 test for categorical variables, Student’s T-test for normally distributed
continuous variables and Wilcoxon Test for skewed continuous or ordinal
variables
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Discussion
This is one of the ﬁrst studies to investigate separately in
elderly women and men the association between late-
onset depressive symptom dimensions and pre-AD
deﬁned retrospectively from expert-panel validated AD
diagnoses. Overall, our ﬁndings suggest a differential
pattern of associations according to sex and depression
status, assessed by overall depressive symptomatology and
AA use. In high DS women, the four dimensions were
signiﬁcantly associated with pre-AD in the untreated but
not in the treated women. This was also the case for
depressed affect in the low DS women. In addition,
somatic affect stood out as the most robust marker of pre-
AD in low symptomatology women and men, whatever
their treatment status.
The pre-dementia phase: methodological considerations
and study design
When studying depression as a potential marker of pre-
dementia, the deﬁnition of the period associated with this
phase is crucial as the type and intensity of depressive
symptoms may change over time. Based on recent ﬁnd-
ings from large prospective studies6,9,46, we chose to tar-
get the 3–4 year time-period before the diagnosis in order
to closely capture the pre-AD phase and avoid con-
founding with the dementia state. To date, most studies
show considerable variability in time-to-event even within
a restricted time-frame as few have adopted a time-
dependent approach to examine the depression-dementia
association. Furthermore, to our knowledge, no studies
have allowed for an intermediate diagnosis-free time-
point between the pre-AD depression assessment and the
dementia onset period. The 2-year diagnosis-free time-lag
in our study reduced the risk of capturing a concomitant
onset of both conditions.
Depressive symptom dimensions and pre-AD dementia
Few studies have examined depression dimensions with
respect to dementia onset5,16,18 and the use of different
depression scales, with varying numbers and types of
symptom dimensions limits the comparability of ﬁnd-
ings19. In a cohort of 3410 elderly participants, Li et al.
(2011) found that any score > 0 on the depressed affect
dimension of the 11-item CES-D version was associated
with a 3-year increased risk of dementia5. In a ﬁve-year
follow-up study of 437 never-depressed elderly, out of the
nine DSM-IV-TR depressive symptoms, only ‘loss of
interest’ was associated with AD onset16. This symptom
was not included in the original 20-item CES-D, thus
making comparisons spurious. However, neither of these
studies took into account time-to-diagnosis or considered
depressive symptomatology as a time-dependent variable.
Sex differences in low versus high DS groups
Sex differences in the association between depression
and pre-dementia have seldom been examined. Overall,
ﬁndings are contradictory as to the existence6,7,12 and
direction10,25 of sex differences in the association between
late-life depressive symptoms measured using the CES-D
and pre-AD. Conversely, to studies suggesting associa-
tions in men but not women10,25, we found in a larger
dataset with a greater number of incident AD cases an
association in women only. These contradictory ﬁndings
may be explained by differences in the study populations,
for example with respect to age, education, and baseline
cognitive functioning. Studies also vary in their metho-
dological approach, focusing on late-life rather than late-
onset depression and not always allowing for a diagnosis-
free time-lag between assessment and dementia onset10.
Table 2 Risk of incident AD pre-dementia associated with
time-dependent depression dimensions (separate models
for each dimension) and depressive symptomatology
items HR (95%CI) pc
Women (294 events/3374)
Depression dimensions
Somatic affecta (1, 2, 5, 7, 11,
13, 20)
1.08 (1.02;1.14) 0.007
Depressed affecta (3, 6, 14,
17, 18)
1.05 (1.01;1.10) 0.02
Positive affectb (4, 8, 12, 16) 1.04 (1.00;1.08) 0.04
Interpersonal challenge (9, 10, 15, 19) 1.08 (1.00;1.16) 0.04
Total score 1.10 (1.03;1.07) 0.003
Depressive
symptomatology: high
(Total
score ≥ 16)
1.39 (1.08;1.80) 0.01
Men (139 events/2243)
Depression dimensions
Somatic affecta (1, 2, 5, 7, 11,
13, 20)
1.08 (0.96;1.19) 0.14
Depressed affecta (3, 6, 14,
17, 18)
0.98 (0.88;1.10) 0.72
Positive affectb (4, 8, 12, 16) 1.02 (0.96;1.09) 0.58
Interpersonal challenge (9, 10, 15, 19) 1.07 (0.92;1.23) 0.41
Total scorea 1.06 (0.93;1.20) 0.38
Depressive
symptomatology: high
(Total
score ≥ 16)
0.92 (0.50;1.68) 0.79
astandardised to 0–12 scale
breversed so that a high score reﬂects a low positive affect
cCox proportional hazard models with age as the time-scale, adjusted for study
centre, education (>5 years), Apoe4 and the following time-dependent variables:
diabetes (no/yes), ischemic disease (no/yes), dependency (3 levels), anxiolytic or
antidepressant consumption (no/yes)
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Table 3 Risk of incident AD pre-dementia associated with time-dependent depression dimensions (separate models for
each dimension), stratiﬁed by depressive symptomatology and antidepressant or anxiolytic (AA) medication use
Women (n events/N) Men (n events/N)
HR (95% CI) pe HR (95% CI) pe
Depressive symptomatology: Lowa 164/1902 118/1744
Somatic affectc 1.22 (1.08;1.38) 0.002 1.30 (1.14;1.48) 0.0001
Depressed affectc 1.15 (1.02;1.29) 0.02 1.01 (0.82;1.25) 0.92
Positive affectd 1.05 (0.98;1.13) 0.19 1.02 (0.94;1.12) 0.60
Interpersonal challenge 1.03 (0.86;1.24) 0.74 1.27 (1.02;1.58) 0.03
Total scorec 1.36 (1.12;1.64) 0.002 1.38 (1.10;1.74) 0.006
AA use: Nob 112/1432 99/1495
Somatic affectc 1.14 (0.98;1.32) 0.09 1.26 (1.08;1.47) 0.004
Depressed affectc 1.28 (1.12;1.47) 0.0004 0.94 (0.73;1.21) 0.62
Positive affectd 1.04 (0.95;1.14) 0.36 0.99 (0.90;1.10) 0.99
Interpersonal challenge 1.05 (0.85;1.30) 0.65 1.16 (0.87;1.53) 0.31
AA use: Yesb 52/470 19/249
Somatic affectc 1.37 (1.09;1.72) 0.008 1.51 (1.14;1.99) 0.004
Depressed affectc 0.97 (0.78;1.21) 0.79 1.59 (1.03;2.45) 0.04
Positive affectd 1.08 (0.95;1.22) 0.25 1.12 (0.92;1.37) 0.25
Interpersonal challenge 0.93 (0.66;1.31) 0.68 1.77 (1.22;2.59) 0.003
Depressive symptomatology: Higha 130/1472 21/499
Somatic affectc 1.11 (1.03;1.19) 0.009 0.97 (0.78;1.20) 0.77
Depressed affectc 1.09 (1.03;1.15) 0.002 1.11 (0.95;1.30) 0.20
Positive affectd 1.08 (1.02;1.15) 0.005 1.16 (1.01;1.34) 0.03
Interpersonal challenge 1.13 (1.04;1.23) 0.003 1.05 (0.82;1.35) 0.70
Total scorec 1.18 (1.08;1.29) 0.002 1.15 (0.91;1.45) 0.25
AA use: Nob 61/714
Somatic affectc 1.17 (1.05;1.31) 0.007 –
Depressed affectc 1.15 (1.07;1.25) 0.0004 –
Positive affectd 1.10 (1.02;1.19) 0.02 –
Interpersonal challenge 1.26 (1.12;1.41) 0.0001 –
AA use: Yesb 69/758
Somatic affectc 1.08 (0.97;1.20) 0.18 –
Depressed affectc 1.04 (0.96;1.12) 0.34 –
Positive affectd 1.07 (0.99;1.16) 0.08 –
Interpersonal challenge 1.03 (0.91;1.16) 0.65 –
afor pre-AD dementia subjects: a high versus low depressive symptomatology was deﬁned as a CES-D score ≥ 16 at assessment point or at any earlier follow-up,
including study entry; for others: this was deﬁned as a CES-D score ≥ 16 at the 2, 4 or 7-year follow-up
bfor pre-AD dementia subjects: AA use was deﬁned as use of AA medication at assessment point or at any earlier follow-up, including study entry; for others: this was
deﬁned as use at the 2, 4 or 7-year follow-up
cstandardised to 0–12 scale
dreversed so that a high score reﬂects a low positive affect
eCox proportional hazard model with age as the time-scale, adjusted for study centre, education (>5 years), Apoe4 and the following time-dependent variables:
diabetes (no/yes), ischemic disease (no/yes), dependency (3 levels)
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Differential ﬁndings in men and women can be expec-
ted as they differ with respect to the type and intensity of
depressive symptoms, and the 16+ threshold for the CES-
D will encompass different symptom proﬁles in each sex.
Furthermore, they differ with respect to symptom
reporting, symptom recognition and treatment. Symp-
toms in men are less likely to be recognised and treated, as
shown by the low absolute number of men reporting AA
treatment in our study (5 out of 21 DS+men). Also, men
may be less willing to admit to experiencing symptoms,
and those scoring high on the CES-D may be reporting
symptoms linked to other chronic diseases, rather than
depression per se47. Differential mortality levels and pat-
terns in men and women over the follow-up will also
inﬂuence the relationship between depressive symptoms
and pre-dementia.
Interpersonal 
challenge
Positive affect
Depressed 
affect
Somatic affect
p=0.0006 *
p=0.006 *
p=0.05
p=0.0002 *
p=0.005 *
p=0.04
p=0.01
p=0.005 *
p=0.04
p=0.007 *
p=0.05
p=0.009 *
Fig. 1 Multi-adjusted associations between individual depression symptoms and pre-AD dementia–women. *signiﬁcant when applying Bonferroni
correction (with p-value thresholds: p ≤ 0.007 for the somatic dimension and p ≤ 0.01 for the depressed affect, positive affect and interpersonal
challenge dimensions)
Interpersonal 
challenge
Positive affect
Depressed 
affect
Somatic affect
p=0.02
p=0.01
p=0.003 *
p=0.006 *
Fig. 2 Multi-adjusted associations between individual depression symptoms and pre-AD dementia–men. *signiﬁcant when applying Bonferroni
correction (with p-value thresholds: p ≤ 0.007 for the somatic dimension and p ≤ 0.01 for the depressed affect, positive affect and interpersonal
challenge dimensions)
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Sex differences according to depressive dimensions
The overall association found in our study in women but
not men hides signiﬁcant associations in both when
examining the symptom dimensions separately in each of
the DS categories. This justiﬁes the need to look beyond
depressive symptomatology as a single entity binary vari-
able. No studies so far have examined the different symp-
tom dimensions according to sex. We found that in low DS
groups, somatic affect was associated with pre-AD in both
women and men. Conversely, the most depression-speciﬁc
dimension, depressed affect, was signiﬁcant in women only
and interpersonal challenge in men only. The greatest
differences concerned the high DS group where highly
signiﬁcant associations were found for the four dimensions
in women, speciﬁcally those untreated.
So far, antidepressant treatment has been mainly ana-
lysed as a confounder, usually measured at a ﬁxed time-
point. Fuhrer et al. (2003) studied the joint effects of time-
dependent depressive symptoms (CES-D score ≥ 23 for
women and ≥ 17 for men) and antidepressant medication
on AD dementia; with the ‘no depression-no treatment’
group as the reference category, they reported signiﬁcant
associations for all three depression-treatment combina-
tions for men only10. However, the low number of parti-
cipants per group calls for caution in interpreting their
ﬁndings. Furthermore, physician prescription behaviour
and patient treatment may differ between the sexes.
Depressive symptoms and pre-AD according to depression
status
In keeping with studies suggesting a differential pattern
of depressive symptoms in subjects with dementia17,
varying according to depression itself18, we examined
associations for individual symptoms according to overall
DS and AA use. In women with high DS, associations for
all four dimensions were restricted to those not taking
AA, in particular depressed affect items ‘Depressed’ and
‘Blues’, and somatic affect item ‘Mind’; this was also the
case for depressed affect in low DS women. This may
suggest a positive effect of AA treatment on cognition,
whatever the overall DS. AA medication may potentially
help delay dementia onset by altering the mechanisms
linking depressive symptoms to dementia: for instance,
through shared risk factors such as cerebrovascular dis-
ease and inﬂammation48, or a causal effect of depressive
symptoms on the dementia process through hippocampal
damage49. An alternative explanation is that pre-dementia
may reduce the likelihood of receiving AA treatment,
either because pre-demented subjects do not seek treat-
ment or because symptoms are attributed to other causes,
such as cognitive decline.
Somatic affect stood out as the most robust marker of
pre-AD in low DS women and men, whatever their
treatment status, although time-dependent dependency
level seldom considered in other studies as a covariate
may have confounded the association for the untreated
women. Several individual symptoms were associated
with pre-AD, but only ‘Mind’ in both sexes and ‘Bothered’
in women remained signiﬁcant after multiple comparison
correction. This suggests that somatic symptoms poten-
tially attributable to other conditions than depression
could be involved. This is in keeping with Lugtenburg
et al. (2015) who reported that the cognitive/motivational
depression dimension identiﬁed using the GMS-
AGECAT predicted 3-year incident dementia, but in
non-depressed elderly only18. They concluded that cog-
nitive and motivational symptoms of depression were
likely to reﬂect cognitive complaints, particularly in the
absence of depression.
CES-D factor structure
Different factor structures have been proposed for the
CES-D, varying according to the number of dimensions
and dimension-speciﬁc items26. Contrary to studies which
apply Radloff’s original 20-item 4-factor structure34,36, we
used the modiﬁed 4-factor structure (Model [B])26, with
items 9 (Failure) and 10 (Fearful) classiﬁed in the inter-
personal challenge rather than depressed affect dimen-
sion. Conﬁrmatory factor analysis revealed that this model
had one of the best factorial validities26. It also had similar
factorial validity compared to the original model in our
study. We nonetheless reran our analyses using the ori-
ginal 20-item 4-factor structure. Our ﬁndings were
unchanged except for the two-item interpersonal chal-
lenge dimension (score 0/1+), which was no longer sig-
niﬁcant for DS– men (data not shown).
Limitations
Several limitations must be taken into account in our
study. To start, we relied on the self-report but validated
CES-D scale rather than on a psychiatric interview to
assess depressive symptomatology. We applied the widely
used 16+ cut-off to distinguish subjects with low versus
high DS. Despite its good psychometric properties, a CES-
D score ≥16 is not equivalent to a clinical diagnosis of
major depression47. We also repeated our analyses with
the French-validated 17+ (for men) and 23+ (for women)
thresholds50; our ﬁndings were largely unchanged. Sec-
ondly, in order to capture a more homogenous group of
subjects and focus on late-onset depression only, we
excluded participants with a history of major depression.
Our ﬁndings were unchanged, albeit less signiﬁcant, when
performing a sensitivity analysis including all subjects.
Thirdly, pre-demented participants may differentially
report depressive symptoms, thus modifying the associa-
tions with pre-dementia. Fourthly, unmeasured con-
founding bias is always possible and may have altered our
ﬁndings. We thus calculated E-values for the signiﬁcant
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multi-adjusted parameters in Table 251. The strength of
the association that an unmeasured confounder would
require to ‘explain away’ the observed associations, inde-
pendently of the many covariates already taken into
account, suggests this is unlikely. Extreme caution is
nevertheless required for the interpretation of our ﬁnd-
ings and causality can by no means be assessed. Finally, a
difference in attrition with participants who will go on to
develop dementia being more likely to be censored than
others is a further limitation potentially leading to an
underestimation of the associations.
Strengths
On the other hand, this prospective study was based on
a large community sample with six assessments per-
formed over 12 years including a clinical examination at
each time-point. The large sample size allowed us to
perform our analysis on a homogenous group of pre-AD
participants, stratiﬁed by sex, despite the lower number of
events in men. We were also able to consider overall
symptomatology and treatment, and into account a
number of time-dependent covariates in our analysis. An
additional strength is the validation of probable dementia
cases by an expert panel of clinicians, given the low sen-
sitivity of case-records for identifying cases6,9.
Conclusion
Our ﬁndings highlight sex-speciﬁc associations between
depression dimensions, speciﬁc symptoms and pre-AD,
which vary according to the overall symptom level and
treatment. In women, the most depression-speciﬁc
dimension, depressed affect, was a marker of pre-AD in
the absence of treatment only. The least depression-
speciﬁc dimension, somatic affect, stood out as the most
robust marker of pre-AD in both women and men with
low symptomatology. Assessment of speciﬁc symptoms,
as well as overall depressive symptomatology and treat-
ment, could help identify high-risk AD dementia proﬁles
likely to beneﬁt from interventions.
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